| 5.38 -0.005 (-0.09%) | 08-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Third Harmonic Bio, Inc. is a clinical-stage biotechnology firm dedicated to creating therapeutic solutions for a range of allergic and inflammatory conditions. Their primary investigational compound is THB001, an orally administered small-molecule inhibitor targeting KIT. This compound is being advanced to address chronic urticaria—a skin ailment characterized by painful, itchy red welts (hives) stemming from mast cell overactivity—and is also being explored for its potential in respiratory and digestive tract disorders. Previously known as Project IGE, Inc., the company adopted its current name, Third Harmonic Bio, Inc., in June of 2019. Established in 2019, its corporate headquarters are situated in Cambridge, Massachusetts.
Fri, 08 May 2026
Natalie Holles' next move after Third Harmonic shutdown; Mark Alles passes the torch at ADC biotech - Endpoints News
Mon, 21 Jul 2025
Third Harmonic Bio to delist from Nasdaq and announces liquidation distribution - Investing.com
Wed, 16 Apr 2025
SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE
Tue, 15 Apr 2025
Big moves by small biotechs signal potential shift for investors - San Francisco Business Times - The Business Journals
Tue, 15 Apr 2025
Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter
Mon, 14 Apr 2025
Third Harmonic’s song to end as biotech looks to liquidate, sell off urticaria drug - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|